DoW Melanoma Research Program Survivorship Research Award
- Response deadline
- Oct 14, 2026 Due in 40 days
- Date posted
- May 21, 2026
- Source
- Open notice
Description
Summary: The fiscal year 2026 (FY26) Melanoma Research Program (MRP) Survivorship Research Award addresses the relatively new and underfunded area of melanoma-specific survivorship by supporting a broad range of innovative and impactful research that has the intended outcome of improving the health and well-being of melanoma survivors, their families and/or their care partners in the near term. Proposed studies focusing exclusively on animal models or considering survival only without consideration of quality of life, overall health and/or function are not responsive to this funding opportunity. Distinctive Features: · The application must include at least one melanoma consumer collaborator , defined as a melanoma survivor, family member and/or care partner who can provide lived experience expertise to the research project team, or a melanoma-community supporting organization to support the planning, execution, and implementation of the proposed research. · Clinical trials are allowed.
Classifications
- NAICS12.420
Documents (1)
- DownloadHT942526MRPSRA_GG.pdfapplication/pdf741 KB
Contacts
- help@ebrap.org301-619-1139
Similar contracts
- DoW Breast Cancer, Clinical Research Extension AwardDue Nov 18, 2026
- DoW Breast Cancer, Breakthrough Award Levels 1 and 2Due Nov 18, 2026
- DoW Reconstructive Transplant, Investigator-Initiated Research AwardDue Nov 4, 2026
- DoW Neurofibromatosis Synergistic Idea AwardDue Sep 22, 2026
- DoW Neurofibromatosis Investigator-Initiated Research AwardDue Sep 22, 2026
- DoW Neurofibromatosis Exploration-Hypothesis Development AwardDue Sep 22, 2026